NEXGEL (NXGL) said Monday it is expanding its collaboration with European consumer health company STADA Arzneimittel to launch new digestive enzyme formulas and products for scars and stretch marks.
As part of the deal, STADA will provide NEXGEL with $1 million in non-dilutive funding to support product launches and marketing efforts, the company said.
Shares of NEXGEL were down 1.5% in recent Monday trading.
Price: 2.65, Change: -0.04, Percent Change: -1.48
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.